XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and Other Agreements - Incyte Corporation (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended 51 Months Ended
Jan. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
USD ($)
performanceObligation
Mar. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Collaboration And Other Agreements [Line Items]                  
Revenues   $ 11,101,000 $ 16,881,000            
Deferred revenue, current   25,562,000       $ 20,646,000   $ 25,562,000  
Deferred revenue, net of current portion   6,364,000       0   6,364,000  
Incyte Corporation | Incyte MGA012 Agreement                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment         $ 150,000,000        
Potential development and regulatory milestone payments under agreement             $ 420,000,000    
Potential commercial milestone payments under agreement             $ 330,000,000    
Development and regulatory milestones recognized     10,000,000         70,000,000  
Number of performance obligations | performanceObligation             2    
Collaborative agreement transaction price             $ 154,000,000    
Variable consideration recognized             $ 4,000,000    
I-Mab | I-Mab Biopharma Collaboration and License Agreement                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment       $ 15,000,000          
Potential development and regulatory milestone payments under agreement                 $ 135,000,000
Development and regulatory milestones recognized   5,000,000       5,000,000      
Revenues   200,000 600,000            
Deferred revenue   4,400,000       $ 4,500,000   4,400,000  
Minimum | Incyte Corporation | Incyte MGA012 Agreement                  
Collaboration And Other Agreements [Line Items]                  
Potential proceeds from royalties (percent)         15.00%        
Maximum | Incyte Corporation | Incyte MGA012 Agreement                  
Collaboration And Other Agreements [Line Items]                  
Potential proceeds from royalties (percent)         24.00%        
Maximum | I-Mab | I-Mab Biopharma Collaboration and License Agreement                  
Collaboration And Other Agreements [Line Items]                  
Potential proceeds from royalties (percent)       20.00%          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                  
Collaboration And Other Agreements [Line Items]                  
Revenues         $ 150,000,000        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities                  
Collaboration And Other Agreements [Line Items]                  
Revenues   0              
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                  
Collaboration And Other Agreements [Line Items]                  
Revenues   300,000 100,000            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement                  
Collaboration And Other Agreements [Line Items]                  
Revenues     $ 3,100,000            
RevenuesFromCMOAgreementsMember | Incyte Corporation                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment $ 10,000,000                
Revenues   0              
Deferred revenue   11,200,000           11,200,000  
Deferred revenue, current   4,800,000           4,800,000  
Deferred revenue, net of current portion   6,400,000           6,400,000  
Annual Fixed Payments   $ 14,400,000           $ 14,400,000